drugset
drugset / Trial / NCT00003850

Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00003850 ↗

Phase 2 Completed 47 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial to study the effectiveness of thalidomide in treating patients with recurrent or metastatic head and neck cancer. Thalidomide may stop the growth of head and neck cancer by stopping blood flow to the tumor.

Timeline

Start
1999-04
Primary completion
2003-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Thalidomide Other / unclassified — Oral

Indications

head and neck cancer